Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

被引：20

作者：

Delabaudiere, Cyrielle ^{[1
]}

Lavayssiere, Laurence ^{[1
]}

Doerr, Gaelle ^{[1
]}

Muscari, Fabrice ^{[2
,3
]}

Danjoux, Marie ^{[4
]}

Sallusto, Federico ^{[5
]}

Peron, Jean Marie ^{[3
,6
]}

Bureau, Christophe ^{[3
,6
]}

Rostaing, Lionel ^{[1
,3
,7
]}

Izopet, Jacques ^{[3
,7
,8
]}

Kamar, Nassim ^{[1
,3
,7
]}

机构：

[1] CHU Rangueil, Dept Nephrol & Organ Transplantat, F-31059 Toulouse 9, France

[2] Univ Hosp Rangueil, Dept Surg & Liver Transplantat, Toulouse, France

[3] Univ Toulouse 3, F-31062 Toulouse, France

[4] CHU Purpan, Dept Pathol, Toulouse, France

[5] CHU Rangueil, Dept Urol & Kidney Transplantat, F-31059 Toulouse 9, France

[6] CHU Purpan, Dept Hepatol, Federat Digest, Toulouse, France

[7] CHU Purpan, IFR BMT, INSERM, U1043, Toulouse, France

[8] CHU Purpan, Virol Lab, Toulouse, France

来源：

TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 02期

关键词：

fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir; RECIPIENTS; THERAPY; PEGINTERFERON; INFECTION; ALPHA;

D O I：

10.1111/tri.12428

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.

引用

页码：255 / 258

页数：4

共 50 条

[21] HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation
Coilly, Audrey
Sebagh, Mylene
Fougerou-Leurent, Claire
Pageaux, Georges-Philippe
Leroy, Vincent
Radenne, Sylvie
Silvain, Christine
Lebray, Pascal
Houssel-Debry, Pauline
Cagnot, Carole
Rossignol, Emilie
Danjou, Helene
Veislinger, Aurelie
Samuel, Didier
Duclos-Vallee, Jean-Charles
Dumortier, Jerome
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (09)
[22] Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
Maruyama, Anna
Hussaini, Trana
Partovi, Nilufar
Erb, Siegfried R.
Azalgara, Vladimir Marquez
Zalunardo, Nadia
Pick, Neora
Hull, Mark
Yoshida, Eric M.
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2016, 2016
[23] Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C
Satsangi, Sandeep
Mehta, Manu
Duseja, Ajay
Taneja, Sunil
Dhiman, Radha K.
Chawla, Yogesh
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (04) : 859 - 863
[24] Fibrosing Cholestatic Hepatitis in HIV/HCV Co-Infected Transplant Patients-Usefulness of Early Markers After Liver Transplantation
Antonini, T. M.
Sebagh, M.
Roque-Afonso, A. M.
Teicher, E.
Roche, B.
Sobesky, R.
Coilly, A.
Vaghefi, P.
Adam, R.
Vittecoq, D.
Castaing, D.
Samuel, D.
Duclos-Vallee, J. -C.
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (08) : 1686 - 1695
[25] Ribavirin/interferon-α sequential treatment of recurrent hepatitis C after liver transplantation
Giostra, E
Kullak-Ublick, GA
Keller, W
Fried, R
Vanlemmens, C
Kraehenbuhl, S
Locher, S
Egger, HP
Clavien, PA
Hadengue, A
Mentha, G
Morel, P
Negro, F
TRANSPLANT INTERNATIONAL, 2004, 17 (04) : 169 - 176
[26] Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe-cryoglobulinemia in a liver/kidney transplant recipient
Montalbano, Marzia
Pasulo, Luisa
Sonzogni, Aurelio
Remuzzi, Giuseppe
Colledan, Michele
Strazzabosco, Mario
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (02) : 216 - 220
[27] Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon
Sven C. Schmidt
Marcus Bahra
Sandra Bayraktar
Thomas Berg
Maximilian Schmeding
Johann Pratschke
Peter Neuhaus
Ulf Neumann
Digestive Diseases and Sciences, 2010, 55 : 2063 - 2069
[28] Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation
Tame, Mariarosa
Buonfiglioli, Federica
Del Gaudio, Massimo
Lisotti, Andrea
Cecinato, Paolo
Colecchia, Antonio
Azzaroli, Francesco
D'Errico, Antonietta
Arena, Rosario
Calvanese, Claudio
Quarneti, Chiara
Ballardini, Giorgio
Pinna, Antonio Daniele
Mazzella, Giuseppe
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (32) : 5278 - 5285
[29] Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation
Shinoda, Masahiro
Ebinuma, Hirotoshi
Itano, Osamu
Yamagishi, Yoshiyuki
Obara, Hideaki
Kitago, Minoru
Nakamoto, Nobuhiro
Hibi, Taizo
Yagi, Hiroshi
Abe, Yuta
Matsubara, Kentaro
Chu, Po-sung
Wakayama, Yuko
Taniki, Nobuhito
Yamaguchi, Akihiro
Amemiya, Ryusuke
Miyake, Rei
Mizota, Takamasa
Kanai, Takanori
Kitagawa, Yuko
HEPATOLOGY RESEARCH, 2016, 46 (11) : 1118 - 1128
[30] Treatment of Genotype 4 Hepatitis C Recurring After Liver Transplantation Using a Combination of Pegylated Interferon Alfa-2a and Ribavirin
Waleed Al-hamoudi
Hazem Mohamed
Faisal Abaalkhail
Yaser Kamel
Nasser Al-Masri
Naglaa Allam
Saleh Alqahtani
Mohammed Al-Sofayan
Hatem Khalaf
Mohammed Al-Sebayel
Ahmed Al-jedai
Ayman Abdo
Digestive Diseases and Sciences, 2011, 56 : 1848 - 1852

← 1 2 3 4 5 →